Northborough, MA, United States of America

Yuliya Kutskova

This inventor holds 18 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Monoclonal Antibodies. Top assignees: Abbvie Inc., Abbvie Deutschland Gmbh and Co Kg, Abbott Laboratories Corporation. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuliya Kutskova. Retrieved from https://idiyas.com/inventor/yuliya-kutskova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 11)

% Patents Active = 77.8

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 1 (Patent Applications = 12)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 112(Granted Patents)

Company Filing History:

Abbvie Deutschland Gmbh and Co Kg

patents

1 out of 4,190

Abbott Laboratories Corporation

patents

4. 1 out of 6

Calico Life Sciences LLC

patents

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

Anti-PAPP-A Antibodies

Monoclonal Antibodies

IL-17 Binding Proteins

Bispecific Antibodies

Therapeutic DLL4 Proteins

Immunobinders

RNA Display

Antibody Libraries

Repulsive Guidance Molecule A

Sclerostin

Neurite Degeneration

Dual-Specific Antibodies

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12157776 - Anti-PAPP-A antibodies and methods of use thereof (2024-12-03),

2. 10106602 - Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof (2018-10-23),

3. 9803009 - Immunobinders directed against TNF (2017-10-31),

4. 9663587 - IL-17 binding proteins (2017-05-30),

5. 9655964 - Bispecific antibodies directed against TNF-α and IL-17 (2017-05-23),

6. 9481736 - IL-17 binding proteins (2016-11-01),

7. 9481735 - IL-17 binding proteins (2016-11-01),

8. 9469688 - Therapeutic DLL4 binding proteins (2016-10-18),

9. 9365643 - Antibodies that bind to repulsive guidance molecule A (RGMA) (2016-06-14),

10. 9132190 - Therapeutic DLL4 binding proteins (2015-09-15),

11. 9102722 - Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration (2015-08-11),

12. 8999331 - Immunobinders directed against sclerostin (2015-04-07),

13. 8916504 - Methods of RNA display (2014-12-23),

14. 8835610 - IL-17 binding proteins (2014-09-16),

15. 8779101 - IL-17 binding proteins (2014-07-15),

Title: The Innovative Contributions of Yuliya Kutskova

Yuliya Kutskova, an accomplished inventor based in Northborough, MA, has made significant strides in the field of biotechnology with a remarkable portfolio of 18 patents. Her innovative work focuses on developing antibodies that address serious health issues, particularly in the realm of kidney disease and neurite degenerative disorders.

Latest Patents

Yuliya’s latest patents include groundbreaking advancements in the medical field. One of her notable inventions is the patent for anti-PAPP-A antibodies and methods of use thereof. This innovation provides antibodies aimed at treating PAPP-A associated disorders, such as kidney disease. Another significant patent she holds involves isolated monoclonal anti-repulsive guidance molecule A antibodies and their applications. This invention facilitates the treatment and diagnosis of neurite degenerative diseases and disorders, showcasing her expertise in addressing complex health challenges.

Career Highlights

Throughout her career, Yuliya has contributed her talents to prominent companies such as AbbVie Inc. and Abb Vie Deutschland GmbH & Co. KG. Her experience in these organizations has strengthened her knowledge and skills, allowing her to lead pioneering research projects and innovative developments in biotechnology.

Collaborations

Yuliya has collaborated with several esteemed professionals in her field, including Chung-Ming Hsieh and John Memmott. These partnerships have fostered a dynamic environment for research and development, enabling her to create impactful solutions in medical science.

Conclusion

Yuliya Kutskova stands out as a leading inventor, making notable contributions to biotechnology through her innovative patents. With her continued dedication to research and collaboration, she is poised to influence the future of medical treatments significantly. Her work not only reflects her expertise but also her commitment to improving health outcomes for individuals facing challenging medical conditions.

Profile summary based on public USPTO records.